Diversified Trust Co cut its position in Zoetis Inc. (NYSE:ZTS) by 28.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,790 shares of the company’s stock after selling 4,645 shares during the period. Diversified Trust Co’s holdings in Zoetis were worth $735,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Wendell David Associates Inc. increased its position in Zoetis by 23.1% in the second quarter. Wendell David Associates Inc. now owns 8,000 shares of the company’s stock valued at $499,000 after buying an additional 1,500 shares during the period. Louisiana State Employees Retirement System increased its position in Zoetis by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 30,400 shares of the company’s stock valued at $1,896,000 after buying an additional 200 shares during the period. Jarislowsky Fraser Ltd increased its position in Zoetis by 3.9% in the second quarter. Jarislowsky Fraser Ltd now owns 171,903 shares of the company’s stock valued at $10,723,000 after buying an additional 6,450 shares during the period. Dixon Hubard Feinour & Brown Inc. VA increased its position in Zoetis by 2.8% in the second quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 12,265 shares of the company’s stock valued at $765,000 after buying an additional 330 shares during the period. Finally, Ardevora Asset Management LLP bought a new position in Zoetis during the second quarter valued at approximately $28,801,000. Institutional investors and hedge funds own 95.10% of the company’s stock.

Shares of Zoetis Inc. (NYSE:ZTS) traded up 0.32% during trading on Thursday, hitting $62.62. 270,587 shares of the stock were exchanged. The company has a market cap of $30.73 billion, a price-to-earnings ratio of 36.41 and a beta of 1.03. Zoetis Inc. has a one year low of $46.86 and a one year high of $63.85. The stock’s 50 day moving average price is $62.64 and its 200-day moving average price is $57.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 4th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.48 by $0.05. Zoetis had a net margin of 17.25% and a return on equity of 65.35%. The firm had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period in the prior year, the business posted $0.48 EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post $2.33 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Thursday, June 15th will be issued a $0.105 dividend. The ex-dividend date is Tuesday, June 13th. This represents a $0.42 annualized dividend and a dividend yield of 0.67%. Zoetis’s dividend payout ratio is currently 24.42%.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/07/20/diversified-trust-co-has-735000-stake-in-zoetis-inc-nysezts.html.

Several research analysts have commented on the stock. Cowen and Company set a $60.00 price objective on shares of Zoetis and gave the company a “buy” rating in a report on Tuesday, July 11th. BMO Capital Markets downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and increased their price objective for the company from $64.00 to $65.00 in a report on Tuesday, June 13th. They noted that the move was a valuation call. Jefferies Group LLC increased their price objective on shares of Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, May 9th. CL King initiated coverage on shares of Zoetis in a report on Friday, May 26th. They issued a “buy” rating and a $71.00 price target for the company. Finally, Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a report on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. Zoetis currently has an average rating of “Buy” and an average target price of $63.11.

In other news, insider Catherine A. Knupp sold 5,785 shares of the company’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $60.16, for a total value of $348,025.60. Following the transaction, the insider now directly owns 24,415 shares in the company, valued at approximately $1,468,806.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.31% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.